Abstract
Cancer-associated cognitive dysfunction (CACD) is experienced by up to two-thirds of cancer survivors and may persist for decades following completion of treatment. Cognitive dysfunction in survivors may be subtle and may impact performance in or more cognitive domains; therefore, there is a need for objective measures of function that have adequate sensitivity and specificity to detect cognitive decline in this population. This chapter discusses brief cognitive screening measures and their utility in detecting dysfunction, as well as more comprehensive flexible neuropsychological assessment measures and their use in cancer survivors. The chapter provides a review of research examining the sensitivity and specificity of these measures in the detection of CACD, as well as their effect on patient outcomes, and provides recommendations for future research and the use of flexible neuropsychological assessment batteries in the screening and assessment of CACD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
